Michael Ryskin
Stock Analyst at B of A Securities
(1.57)
# 2,587
Out of 4,667 analysts
34
Total ratings
41.67%
Success rate
-8.1%
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Downgrades: Neutral | $45 → $60 | $58.15 | +3.18% | 2 | Oct 2, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $30.68 | +30.38% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $7.75 | +22.58% | 1 | Jun 25, 2024 | |
| EXAI Exscientia | Downgrades: Neutral | $11 → $9 | $4.84 | +85.95% | 2 | Jan 5, 2024 | |
| MRVI Maravai LifeSciences Holdings | Upgrades: Buy | $10 → $8 | $4.82 | +65.98% | 2 | Dec 12, 2023 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $9.55 | +151.31% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $20.14 | +19.17% | 2 | Jul 31, 2023 | |
| ALGN Align Technology | Maintains: Underperform | $190 → $225 | $223.87 | +0.50% | 5 | Apr 27, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $175.67 | +2.46% | 7 | Nov 4, 2022 | |
| OMIC Singular Genomics Systems | Downgrades: Underperform | $90 | $21.68 | +315.13% | 3 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $550 → $470 | $418.61 | +12.28% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.04 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $19.17 | +171.26% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $2.68 | +273.13% | 2 | Nov 10, 2021 |
Tempus AI
Oct 2, 2024
Downgrades: Neutral
Price Target: $45 → $60
Current: $58.15
Upside: +3.18%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $30.68
Upside: +30.38%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $7.75
Upside: +22.58%
Exscientia
Jan 5, 2024
Downgrades: Neutral
Price Target: $11 → $9
Current: $4.84
Upside: +85.95%
Maravai LifeSciences Holdings
Dec 12, 2023
Upgrades: Buy
Price Target: $10 → $8
Current: $4.82
Upside: +65.98%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $9.55
Upside: +151.31%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $20.14
Upside: +19.17%
Align Technology
Apr 27, 2023
Maintains: Underperform
Price Target: $190 → $225
Current: $223.87
Upside: +0.50%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $175.67
Upside: +2.46%
Singular Genomics Systems
Aug 10, 2022
Downgrades: Underperform
Price Target: $90
Current: $21.68
Upside: +315.13%
May 5, 2022
Downgrades: Neutral
Price Target: $550 → $470
Current: $418.61
Upside: +12.28%
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.04
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $19.17
Upside: +171.26%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $2.68
Upside: +273.13%